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Background: Type 2 diabetes mellitus is a chronic disease whose health outcomes are related to patients and
healthcare professionals’ decision-making. The Diabetes Intervention study in the Canary Islands (INDICA study) aims
to evaluate the effectiveness and cost-effectiveness of educational interventions supported by new technology
decision tools for type 2 diabetes patients and primary care professionals in the Canary Islands.
Methods/design: The INDICA study is an open, community-based, multicenter, clinical controlled trial with random
allocation by clusters to one of three interventions or to usual care. The setting is primary care where physicians
and nurses are invited to participate. Patients with diabetes diagnosis, 18–65 years of age, and regular users of
mobile phone were randomly selected. Patients with severe comorbidities were excluded. The clusters are primary
healthcare practices with enough professionals and available places to provide the intervention. The calculated
sample size was 2,300 patients.
Patients in group 1 are receiving an educational group program of eight sessions every 3 months led by trained
nurses and monitored by means of logs and a web-based platform and tailored semi-automated SMS for continuous
support. Primary care professionals in group 2 are receiving a short educational program to update their diabetes
knowledge, which includes a decision support tool embedded into the electronic clinical record and a monthly
feedback report of patients’ results. Group 3 is receiving a combination of the interventions for patients and professionals.
The primary endpoint is the change in HbA1c in 2 years. Secondary endpoints are cardiovascular risk factors,
macrovascular and microvascular diabetes complications, quality of life, psychological outcomes, diabetes knowledge,
and healthcare utilization. Data is being collected from interviews, questionnaires, clinical examinations, and records.
Generalized linear mixed models with repeated time measurements will be used to analyze changes in outcomes.
The cost-effectiveness analysis, from the healthcare services perspective, involves direct medical costs per
quality-adjusted life year gained and two periods, a ‘within-trial’ period and a lifetime Markov model. Deterministic and
probabilistic sensitivity analyses are planned.
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Discussion: This ongoing trial aims to set up the implementation of evidence-based programs in the clinical setting
for chronic patients.
Trial registration: Clinical Trial.gov NCT01657227
Keywords: Behavior modification, Care management, Decision support aids, Electronic communication,
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Type 2 diabetes mellitusBackground
Type 2 diabetes mellitus (T2DM) is a paradigmatic chronic
disease in which health outcomes are related to patients’
decision-making on adherence to life-style changes and
pharmacologic recommendations. Besides patients, other
relevant stakeholders, such as family members, as well as
healthcare professionals, mainly at the primary care level,
also play a relevant role in supporting patients’ decision-
making.
In the Canary Islands, Spain, the prevalence of T2DM
in the population over 15 years is 7.74%, slightly higher
than the Spanish average (6.99%) [1]. However, the Can-
ary Islands have an increased prevalence of diabetes-
related end-stage renal disease [2-4] and diabetes-related
mortality [5], when compared to the rest of Spain, with
65 vs 20–30 cases/million population and 7.8% vs 2.5%,
respectively. This happens despite the fact that patients
with diabetes mellitus (DM) have a mean number of ten
visits/year to their primary care physician/nurse in the
Canary Islands [6]. Furthermore, public healthcare re-
sources earmarked to care for people with diabetes in
the Canary Islands increased from 2.13% in 1998 to 5.9%
in 2004 [7].
Despite the availability of evidence-based clinical practice
guidelines [8,9] and clinical trials reporting better health
outcomes linked to interventions promoting patients’ self-
care [10,11], international reports still show that only 55%
of people with T2DM receive diabetes education [12]; 16%
adhere to recommended self-management activities [13],
37% meet the glycated hemoglobin (HbA1c) target of
7.0%, and only 7% meet combined glycemic, lipid, and
blood pressure goals [14-17].
The socio-economic and public health consequences
of T2DM in the Canary Islands prompted the Canary
Islands Health Service (CIHS) to assess the effective-
ness and efficiency of new interventions to improve
both patient healthcare outcomes and the sustaina-
bility of publicly funded healthcare services. In this
context, information and communication technology
(ICT) offers the opportunity of efficiently supporting
knowledge transfer and behavior modification inter-
ventions to improve decision-making by T2DM pa-
tients [18-22] and healthcare professionals [23-25].
Indeed, more than 70% of Canary Island families and90% of inhabitants have daily access to internet and
mobile phones, respectively [26].
Although there are many publications addressing the
use of different ICT applications to support patient and
professional decision-making [23,27], few studies have
assessed the health and economic impact of complex
interventions by means of large and long-term ran-
domized clinical trials reporting on effectiveness and
cost-effectiveness.
The Diabetes Intervention study in the Canary Islands
(INDICA study) is a randomized controlled trial (RCT)
that assesses the effectiveness and cost-effectiveness of
three different complex interventions for knowledge
transfer and behavior modification of patients, families,
and healthcare professionals (physicians and nurses) at
the primary care level in the Canary Islands. The interven-
tions include a diabetes-coaching system using a combin-
ation of conventional educational workshops with mobile
phones, a patient web-based platform, electronic decision
aids, and periodic feedback on patients’ outcomes to guide
them and healthcare professionals in decision-making
related to T2DM management.
We hypothesize that this combination of conventional
educational activities complemented with timely and
continuous ICT decision support tools will efficiently
improve disease management skills and behavior, both
in patients and in healthcare professionals, in addition to




The INDICA study is an open, community-based, mul-
ticenter, clinical controlled trial with random alloca-
tion by clusters to usual care or one of the following
different interventions of knowledge transfer and be-
havior modification.
Group 1 corresponds to intervention only for patients
and family members, group 2 to intervention only for
healthcare professionals at primary care, and group 3 is a
combined intervention for patients and professionals. In the
control group, neither patients/families nor physicians/
nurses receive any additional educational or supporting ac-
tivities beyond the usual activities provided by the CIHS.
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Patient inclusion criteria
1) Patients with T2DM diagnosed at least 1 year prior
to study enrolment
2) 18–65 years of age
3) Formal consent to participate in the study
4) Regular use of mobile phonePatient exclusion criteria
1) Chronic kidney disease ≥ stage 3b, as defined by the
National Kidney Foundation’s Kidney Disease
Outcomes and Quality Improvement Initiative
(KDOQI), urinary albumin to creatinine ratio
(UACR) ≥ 300 mg/g, and/or urinary protein
excretion ≥ 300 mg/24 h.
2) Acute coronary syndrome (documented angina or
myocardial infarction) or stroke in the last 6 months
or class III or IV heart failure, according to the New
York Heart Association (NYHA).
3) Proliferative diabetic retinopathy or clinically
significant diabetic macular edema requiring
previous treatment with retinal photocoagulation,
vitrectomy, or intravitreal injections of anti-vascular
endothelial growth factor or triamcinolone acetonide
6 months prior to study inclusion.
4) Uncorrected severe hearing or visual impairment or
corrected visual acuity ≤ 20/40 by any cause.
5) Diabetic foot with ulcers ≥ 2 according to the
Wagner scale.
6) Liver cirrhosis
7) Cancer unless disease free 5 years after diagnosis
8) Other terminal illnesses
9) Intellectual retardation, dementia, psychotic diseases
10) Active substance abuse, alcohol, or drugs (must be
sober for 1 year)
11) Pregnancy
12) Insufficient (Spanish) language skills
13) Physical disability limiting participation in group
education activities
14) Concurrent participation in another clinical trial or
any other investigational study.Primary care professionals
The unit of recruitment for primary care professionals
was the Family Care Unit (FCU), composed of a family
physician and a nurse. Given the interventions’ nature
and the organizational characteristics in primary care at
CIHS, it was agreed that physicians and nurses working
together as FCUs independently sign the informed con-
sent to participate. Family physicians and nurses either
planning or awaiting placement changes among primaryhealthcare practices (PHCP) in the first 6 months after
project initiation were excluded.
Only PHCP with at least eight FCUs and availability
of appropriate places to provide group sessions were
included.
Setting and recruitment
PHCP were randomly recruited in four of the seven
Canary Islands (Tenerife, Gran Canaria, Lanzarote, and
La Palma). Tenerife and Gran Canaria are the main and
most populated islands, providing 12 PHCP each (four
from metropolitan areas, four from the south, and four
from the north). La Palma and Lanzarote are less popu-
lated islands and provided four PHCP each. The Human
Resources Department of the CIHS at every island sup-
plied us with an updated list of publicly available phys-
ician/nurses for every selected PHCP. FCUs’ recruitment
in PHCPs was supported by informative meetings pre-
ceded by meetings with local health authorities as well as
with the directors of all selected PHCP on every island. In
these meetings, a 60–80-min presentation describing the
study objectives, planned time frame and tasks to be de-
veloped by healthcare professionals, expected resources
utilization, and funding procedures were detailed.
After FCUs agreed and consented to participate, the
electronic clinical records (ECR) of all potentially eligible
patients in the selected FCU were screened to verify all
inclusion and exclusion criteria. Once identified, patients
received a phone call to explain the study objectives,
informing that they might be eligible to participate and
inviting them to an initial meeting in their respective
PHCP. In this meeting, the study staff provided face-to-
face extended information about the study, confirmed
patient eligibility, and invited them to sign individual pa-
tient informed consent.
When a participant physician/nurse left their practice,
they were excluded from the study and replaced by the
new physician/nurse. In groups 2 and 3, the educational
intervention was given to the new healthcare professionals
on an individual level. Their corresponding patients were
kept in the study without changes.
Random assignment
Randomization was applied at different levels in every is-
land included in the trial. Three different strata or geo-
graphic areas were set in Tenerife and Gran Canaria
(metropolitan, northern, and southern areas). Four PHCP
were randomly allocated to every stratum. Each PHCP
was assigned to one of the three interventions or control
arms by block permutation. La Palma and Lanzarote were
geographically divided into four zones with only one
PHCP available in each zone. Each of these PHCP was
randomly assigned to one of the study arms. In every is-
land, all arms were equally distributed.
Ramallo-Fariña et al. Implementation Science  (2015) 10:47 Page 4 of 15Six FCUs were randomly selected from all those con-
senting participants at each PHCP. From all patients ful-
filling inclusion criteria and consenting to participate in
each PHCP, 15 were randomly selected per FCU. Excep-
tionally, more than six FCUs or more than 15 patients
per FCU were selected, in order to recruit 90 patients at
every PHCP.
While PHCP randomization was performed using
block permutation at three different levels, second (FCUs)
and third (patients) stage randomizations were performed
by simple generation from a list of random numbers.
PHCP assignment to interventions or control group was
performed by the data manager.
In order to prevent potential contamination among study
interventions, all FCUs at every PHCP were allocated to
the same study group.
Blinding
Participating FCUs were not told about their intervention
assignment (groups 1–4) until the last patient agreed to
participate at every FCU. To warrant patient participation
and cooperation, interventions could neither be blinded to
patients nor to healthcare professionals. Data analysis will
be blinded to the intervention assignment.
Interventions
The study will assess the effectiveness and cost-
effectiveness of three different complex interventions
of knowledge transfer and decision guiding for primary
care healthcare professionals and/or patients and fam-
ilies, according to intervention assignment (Figure 1).
These three interventions are compared with a control
group receiving usual care.
Patient interventions
Groups 1 and 3 receive a complex intervention of know-
ledge transfer and behavior modification combining the
following: A) an educational and interactive group pro-
gram plus continuous monitoring by means of B) daily
use of paper workbooks and weekly utilization of a web-
based platform and C) tailored semi-automated mobile
phone messages.
A) Interactive educational group program:
Patients accompanied, if appropriate, by one family
member responsible for buying food and cooking
and serving meals are invited to receive a set of
eight quarterly 3-h group sessions during the 2 years
of intervention. The aim of this program is to
empower patients in self-control and monitoring
as well as to involve relevant family members in
supporting appropriate decisions about nutritional,
pharmacologic, and physical activity issues. An
experienced nurse, trained in diabetes education,conducts every session, with groups of ten patients
and their corresponding family members. Every
session contains theoretic and practical interactively
delivered activities about the most important diabetes
topics: understanding T2DM, cooking, understanding
nutritional food labels, glycemic target, foot care, drug
adherence, tobacco, stress management, exercise,
chronic complications, etc., according to Funnel
et al.’s recommendations [28]. The specific contents
and procedures of every session were developed based
on several systematic literature reviews. The best
documented and assessed educational interventions
that provided valid and longer term data on
improvements in relevant T2DM health outcomes
were selected [29-31]. In every session, interactive
activities are used to reinforce knowledge transfer
and self-motivation. The first session included
information and training about the adequate use of
the other components of the intervention, such as
the web platform, the workbooks, and the short
message service (SMS) sent to mobile phones. In
order to develop an educational tool for future use
in research or clinical practice, these sessions are
video recorded, after consent of all group participants.
This recording is available on-line to patients.
B) Patient logs for continuous self-monitoring and
periodic reporting:
To provide continuous support to patients and to
reinforce self-care and lifestyle changes, two different
types of workbooks were developed, which show
patients the dynamics and relationships of food intake,
physical activity, and medication adherence with
blood glucose levels. Patients are invited to use a
paper-supported workbook and a web workbook
embedded in a patient web-based platform. The paper
version gathers daily information on the amount of
physical activity, nutritional intake, medication
adherence, mood, blood pressure, and blood glucose
levels. In addition, this information is summarized
and filled in, weekly, in the web workbook, to allow
for continuous monitoring and feedback by means
of automated SMS. Once the web-based questionnaire
is completed, graphical feedback is displayed in the
web platform, showing the variation in all selected
variables over time. The web platform also offers
additional information on diabetes self-management
extracted from the contents of the group educational
program. Additionally, every month, patients are
requested to complete a longer, web-based
questionnaire, collecting information on tobacco
use, foot care, and weight control. This monthly
questionnaire is also used to provide continuous
feedback in the form of automated SMS (see
below). A free phone service is available to fill in
Figure 1 Recruitment according to intervention assignment.
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C) Tailored semi-automated mobile phone messages for
continuous patient support:
Mobile phones are used to warrant reception of
tailored continuous support by means of semi-
automatic periodic delivery of predefined SMS to
support diabetes self-management about healthy
diet, tobacco use, physical activity, treatment
adherence, stress management, and foot care [18].
SMS contents are progressively fitted according to
the topics discussed in the successive group sessions
and to the degree of achievement of the differenttargets required to attain adequate self-management.
SMS are sent weekly, focused on two different
targets each week (eight targets per month). Specific
SMS are selected according to a computer algorithm
that reviews patient compliance for every target
monthly. Compliance is classified as either ‘adequate
control,’ ‘partial improvement,’ or ‘inadequate
control’ for every target. The eight targets with the
poorest results are selected monthly, on a two-per-
week basis. Two messages a week are sent when targets
attained ‘adequate control’ or ‘partial improvement.’
For targets under ‘inadequate control,’ four messages a
week are activated. In addition, all patients receive one
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complete questionnaires every week, up to a maximum
of one SMS a day. The ICT-based interventions
(components B and C of the patient intervention)
were designed according to the best available evidence
by means of a literature review [18,20,32,33].Interventions for primary care physicians and nurses
Primary care professionals (physicians and nurses)
assigned to groups 2 and 3 receive a complex interven-
tion of knowledge transfer and decision-making com-
posed of the following: A) an educational and interactive
group program, B) continuous support by means of an
automated decision aid tool embedded into the elec-
tronic clinical record of patients included, and C) peri-
odic feedback on process and outcome measures for all
T2DM patients of the corresponding FCU.
A) Educational interactive group intervention for FCUs:
The six FCUs (physician-nurse couples) selected in
every PHCP received 5 hours of education, in two
interactive sessions, 3 months apart. The objectives
and contents of the first session are designed to
update evidence-based clinical knowledge on T2DM
management, improve communication and
negotiation abilities, and develop skills to promote
patient-centered care [34] and shared decision-making
[29]. Role-playing exercises with a set of short
video-films representing different types of complex
sham patients are used to deliver this intervention.
The session also includes an explanation about the
use of the automated decision aid tool (see below).
The second session is designed to promote shared
decision-making and motivational interviewing
methods in the context of the patient-centered
care model [29,34]. Shared decision-making is
promoted throughout the sessions to help patients
explore and identify their personal preferences.
These sessions are led by an endocrinologist and a
primary care physician with proven expertise in
communication skills and patient-centered care
methods [35-37]. They are video-recorded in order
to standardize training and to ensure intervention
reliability [38].
The evidence-based information to update knowledge
on clinical management for T2DM was obtained from
the clinical practice guidelines (CPG) of the National
Institute for Health and Clinical Excellence of the
United Kingdom (NICE) [9] and was complemented
with those developed by the American Diabetes
Association (ADA) [8]. These two guidelines were
selected after a process that included 1) a systematic
search of guidelines in several databases (MEDLINE,
PREMEDLINE, Trip Database, GuíaSalud (CPGdatabase in Spain), and National Guideline
Clearinghouse) and 2) the assessment of their
quality by means of the AGREE instrument and
their degree of updating [39]. Contents from
these two CPG were collapsed and contextualized
to obtain the INDICA CPG.
B) Decision support tool embedded in the ECR:
Physicians and nurses have access to an automated
decision support tool (DST) built by means of a
computational algorithm from the previously
developed INDICA CPG and integrated into the
primary care ECR to adapt the recommendations to
the specific needs of every patient included. This
DST is passively activated, providing dynamic and
interactive support for clinical management of
decision-making. The tool is made available for the
15 patients included in every FCU [23-25]. As
previously mentioned, the DST takes into
consideration both the best available scientific
knowledge [8,9] and relevant clinical information
of every patient stored in the ECR (blood pressure,
glucose, and cholesterol levels; renal function,
comorbidities, missed tests or appointments, etc.).
C) Feedback screen:
Every month, physicians and nurses in participating
FCUs receive feedback, consisting of a computer
screen displaying a personalized graphical summary
of relevant processes and outcome indicators
compared to mean results obtained by participating
PHCP [25]. Every month, this informative screen is
automatically displayed when the healthcare
professional switches on his/her work PC. The
screen displays combined indicators, periodically
generated by automated proprietary analytical
models from the ECR of all T2DM patients in the
FCU and not just the 15 study participants.
Process indicators assessed include the
measurements HbA1c, blood pressure, body mass
index (BMI), and lipid profile, as well as the
performance of periodic screening for retinopathy
and nephropathy, according to the INDICA CPG
recommendations. Outcome indicators are based
on the levels of HbA1c, blood pressure, BMI, and
every component of the lipid profile. Outcome
indicators are classified into three levels depending
on whether the patients are in the expected target,
not in target but better than the previous visits, or
out of target and with no improvement. An overall
severity indicator is also calculated by taking into
consideration the number of outcome indicators
out of the expected goal by patient. For every
indicator displayed on the screen, mean reference
values obtained from all FCUs at the same PHCP
are used as dynamic comparators.
Table 1 Outcome measurements according to periods of
follow-up and type of collection
Time Outcome measurements
Outcomes measured on patients
M0, M3, M6, M12, M18,
M24 (F to F)
Demographic data, health history, history
of DM, DM health status, current
medications, risk factors for complications
of poorly controlled DM
Laboratory measurements
M0, M12, M24 (CT) HbA1c; fasting glucose; total cholesterol;
HDL, LDL, and non-HDL cholesterol;
triglycerides; serum creatinine; albumin/
creatinine ratio; and glomerular filtration rate
M3, M18 (CT) HbA1c, fasting glucose
M6 (CT) HbA1c, fasting glucose, total cholesterol,
HDL, LDL cholesterol, and triglycerides
Anthropometric measurements
M0, M3, M6, M12, M18,
M24 (F to F)
BMI, waist/hip ratio, systolic and diastolic
blood pressure, heart rate
Macro and microvascular complications
M0, M12, M24 (F to F, ECR) Incidence of new ischemic heart events,
hospitalization for congestive heart failure,
peripheral artery disease, carotid stenosis
fulfilling criteria for endarterectomy or
confirmed ischemic or hemorrhagic stroke,
incidence or progression of diabetic
retinopathy, incidence or progression of
diabetic nephropathy
Eye examination
M3, M24 (CT) Retinography and macular examination by
OCT
Instruments used for self-reported outcomes measures
M0, M12, M24 (SRI) ADDQoL-19, BDI-II, DES-SF, DDS2, DIATEK,
IPAQ, MEDAS, STAI-S, INDICA-LSQ
(F to F) EQ-5D-5 L, MMAS
M6, M18 (SRI) ADDQoL-19, IPAQ, MEDAS
(F to F) EQ-5D-5 L, MMAS
Healthcare utilization
M0, M3, M6, M12, M18,
M24 (F to F, ECR)
Visits to primary care services, nurses,
specialists; hospital admissions, emergency
room visits, laboratory procedures, and
other diagnostic tests; medication
Satisfaction
M24 (SRI) INDICA-SATP
Outcomes measured on physicians and nurses
M0 (F to F) Demographic data, years in practice,
practice descriptors
M0, T3 (SRI) INDICA-KNOW, LATCon
M24 (SRI) INDICA-SATC
BMI: body mass index; F to F: face to face interview; CT: clinical test; DM: diabetes
mellitus; ECR: electronic clinical records; HDL: high-density lipoprotein;
LDL: low-density lipoprotein; OCT: optical coherence tomography;
SRI: self-reported interview.
Note: see description of the questionnaires in Table 2.
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The primary endpoint of the study is the mean change
in HbA1c from baseline until 24 months later. We con-
sidered a change in HbA1c of 0.4 percentage points to
be clinically significant [40]. In addition to the measure-
ments at baseline and at 24 months, HbA1c is also mea-
sured at 3, 6, 12, and 18 months (Table 1).
Secondary endpoints
A broad set of secondary outcomes are measured
(Table 1), including the following:
– Cardiovascular risk factors: mean change of BMI,
waist circumference, and waist-to-hip ratio, systolic
and diastolic blood pressure, total cholesterol and its
fractions (low-density lipoprotein (LDL), high-
density lipoprotein (HDL), and nonHDL), and tri-
glycerides. Blood pressure is measured twice in one
arm (right when possible) in a sitting position, with
a digital sphygmomanometer trademark OMRON©
model M6, and the average of the two readings will
be recorded. Smoking status is determined by self-
report of whether the subject currently smoked.
– Macrovascular diabetes complications: new ischemic
heart events (angor pectoris, myocardial infarction,
surgical or percutaneous coronary
revascularization), hospitalization for congestive
heart failure, peripheral artery disease (surgical or
percutaneous peripheral arterial revascularization,
nontraumatic lower limb amputation), carotid
stenosis fulfilling criteria for endarterectomy, or
confirmed ischemic or hemorrhagic stroke. The
annual occurrence of cardiovascular events, surgical
procedures, or hospitalization is verified by
reviewing the medical records.
– Microvascular diabetes complications: Incidence
and progression of diabetic nephropathy: mean
change in UACR, UACR ≥ 30 mg/g, mean change
in estimated glomerular filtration rate (eGFR),
eGFR < 60 mL/min/1.73 m2 and need for renal
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according to the results of a retinography, and
incidence and progression of diabetic macular
edema, according to the results of an optical
coherence tomography (OCT) and a retinography,
are measured at months 3 and 24 of the study.
Incidence of diabetic polyneuropathy is measured
using the Michigan Neuropathy Screening
Instrument (MNSI), an emergent instrument used
to assess distal diabetic peripheral polyneuropathy.
Only the 15-item self-administered MNSI, which
is scored by adding up abnormal responses [41]
will be applied. MNSI was translated into andble 2 Instruments used for self-reported outcomes measures
struments Outcome measurements
utcomes measured on patients
EQ-5D-5L [59] Generic HRQoL questionnaire. Th
usual activity, pain/discomfort, an
ADDQoL-19, Audit of Diabetes-
Dependent Quality of life [60]
Specific HRQoL questionnaire for D
physical activities, family life, soc
motivation, reaction from others
reliance on others, freedom to ea
DDS2, Diabetes Distress Scale [61] It is a validated two-item diabete
six-point scale the degree of distr
the demands of living with diabe
STAI-S, State Trait Anxiety Inventory [62] It is a self-description questionnai
(STAI State) and the trait-anxiety s
characterized by subjective feelin
intensity
BDI-II, the Beck Depression Inventory II [63] It is a validated 21-item self-repor




This questionnaire assesses patien
responses on a five-point Likert s
IPAQ, International Physical Activity
Questionnaire. [65]
This questionnaire checks physica
moderate-intensity activities, and
MEDAS, Mediterranean Diet Adherence
Screener [66]
This questionnaire assesses diet r
consumption rated with one poin
MMAS, Morisky Medication Adherence
Scale [67]
This questionnaire assesses the m
an established concurrent and pr
INDICA-SATP Patient satisfaction and usability o
assessed with a specific instrume
Diatek It is a specific instrument created
knowledge about DM based on t
INDICA-LSQ It is a specific instrument created
patients regarding lifestyles, base
utcomes measured on physicians and nurses
LATCon, Leeds Attitude toward
Concordance scale [69]
It is a 12-item self-reported scale to
in medicine-taking
INDICA-KNOW Knowledge change among health
with 20 questions based on the c
INDICA-SATC Acceptability and usability of the
dimensions: acceptability of inter
technology, impact on patients, i
quality of feedback and formats u
T: decision support tool.back-translated from Spanish for its use in the
INDICA study.
– Health-related quality of life (HRQoL), distress,
anxiety, depression, satisfaction with the
interventions, health behaviors, and changes in
knowledge about diabetes self-management: all
instruments selected to measure these outcomes are
reported in Table 2.
– Attitude toward concordance and knowledge about
the clinical management of diabetes: these
instruments, reported in Table 2, are used to
evaluate the interventions on physicians and nurses
included in groups 2 and 3.e self-reported description assesses five domains: mobility, self-care,
d anxiety/depression
M. It assesses 19 domains: leisure activities, working life, travel, holiday,
ial life, personal life, sex life, physical appearance, self-confidence,
, feelings about the future, financial situation, living conditions,
t, and freedom to drink
s distress-screening instrument that asks respondents to rate on a
ess caused by the two following items: (1) feeling overwhelmed by
tes and (2) feeling that I am often failing with my diabetes regimen
re including two non-dependent scales, the applied state-anxiety scale
cale (STAI Trait). It assesses transient emotional state or condition as
gs of tension and apprehension that can fluctuate in time and
t inventory that measures depressive symptoms such as sadness,
ishes, tiredness or fatigue, loss of energy, and loss of pleasure,
t empowerment on T2DM management, including eight items with
cale
l activity and provides information on the time spent on walking,
vigorous and sedentary activities
ecommendation adherence. It consists of 14 targets for food
t for each target achieved
edication adherence, including a four-item self-report measure with
edictive validity
f the web portal and the mobile phone communication system are
nt created in the context of this project
in the context of this project, to assess potential changes in patient
he CPG INDICA
in the context of this project used to assess attitudinal changes of
d in the Transtheoretic Model of Behavior Change [68]
assess patients’ and health professionals’ attitudes toward concordance
care professionals will be measured with the aid of an instrument
ontents of the INDICA CPG
DST and the feedback screen is measured according to four different
actions and time devoted using the software communication
mpact on the clinician’s practice, and communications issues such as
sed [70]
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management of T2DM in all groups will be assessed
from the healthcare services perspective, including the
costs related to the development and use of all compo-
nents for each intervention assessed (group sessions,
ICT system, SMS services, computer-assisted aids, etc.).
The analysis will also include costs because of patient
contacts with primary care services, hospital admissions
and length of stay, outpatient visits, emergency atten-
dances, and prescribed medications. The volume of re-
source used for each cost component will be measured
with the aid of patient questionnaires and ECR; unit
costs will be taken from standard published sources
when available and from the specific providers.
Measurement procedures
Information needed from patients are being collected by
several procedures, including face-to-face interviews,
clinical examinations, analysis of data stored in the ECR,
downloading of information from the INDICA web plat-
form, and self-completed questionnaires. Results of la-
boratory tests will be downloaded from ECR by trained
staff blinded to patient group assignment.
Information needed from FCUs is being obtained by means
of personal interviews and self-reported questionnaires.
The planning of information collection for every out-
come measured throughout the project is shown in
Table 1.
Biochemical determinations
Blood and urine samples are being collected after an
overnight fast, by research nurses, using the available fa-
cilities of the participating PHCPs. After centrifugation,
samples are being immediately transported to the bio-
chemistry laboratory of the corresponding reference hos-
pital. HbA1c is being quantified according to the
Diabetes Control and Complications Trial assay. LDL
cholesterol will be estimated using the Friedewald for-
mula, and nonHDL cholesterol will be calculated as the
difference between total cholesterol and HDL choles-
terol. Estimated glomerular filtration rate will be calcu-
lated using the Modification of Diet of Renal Disease
formula (MDRD4).
Biological samples for future research questions
To facilitate efficient answers to potential future research
questions on T2DM in the Canarian population, urine
and blood samples of patients are being frozen and stored.
This will enable collating a collection of biological speci-
mens from a wide and representative sample of the overall
T2DM population in the Canary Islands. Urine and serum
samples are being obtained at baseline and 24 months,
while DNA samples are only being obtained at baseline.
Every patient will be specifically informed and asked toconsent to storage of DNA and nonDNA biological sam-
ples. These samples are being stored in the biobanks of
the hospitals of the Canary Islands belonging to the Span-
ish National Biobanks Network. This process is in accord-
ance with prevailing Spanish laws on protection of
personal data [42], patient autonomy [43], and biomedical
research [44]. These materials will subsequently be used
to search for genetic or biological markers that could ei-
ther characterize the T2DM patient population or predict
clinical disease course.
Statistical methods
Generalized linear mixed models with repeated time
measurements will be used to analyze changes in out-
comes over time. To compare the three interventions
and the control group after different follow-up periods
(Baseline, 3, 6, 12, 18, and 24 months), the intervention
groups will be treated as a ‘factor within.’ First, we will
examine whether the intervention in Groups 1 and 2 are
better than usual care, and then, we will examine
whether the most intensive intervention (group 3) is bet-
ter than less intensive interventions (groups 1 and 2).
The purpose of these analyses is to obtain preliminary
estimates regarding the incremental benefits of the inter-
vention components [45]. For multiple comparisons, the
P value will be adjusted with Bonferroni correction (Pc
Z corrected value). In addition, the models will include a
subset of covariates that are imbalanced at baseline. To
identify the covariates to be included in the model, we
will first fit separate models including each covariate,
one at a time. The final model will include those covari-
ates such that their inclusion changes the estimates’
treatment effect by at least 10%. As suggested in the
CONSORT statement, decisions about covariates will
not be based on P value [46,47].
To incorporate the effect of cluster analysis, a multi-
level model (MLM) approach will be implemented.
MLM adjusts for the clustering effects across three
levels (patients, FCU, and PHCP) of the hierarchical data
structure.
For the main intention-to-treat analysis comparing
outcomes, all patients will be included. Standard imput-
ation methods (i.e., mean value imputation, last observa-
tion carried forward) will be used to impute missing
data depending on the pattern of missing data. All tests
will be two-sided with a type I error of 5%. Statistical
analyses will be performed using Statistical Package for
social Sciences (SPSS v.21, Chicago, IL, USA).
Sample size calculation We estimated that 393 patients
per arm (total in the study = 1,572) were needed to de-
tect an absolute difference in Hba1c of 0.4%, assuming a
common standard deviation of 1.4% [40], a two-tailed
power of 90%, and an alpha of 0.05. After an additional
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design effect [48], assuming 15 patients per FCU and an
intra-class correlation coefficient of 0.01 (interquartile
range: 0 to 0.032) based on data from the literature [49],
the estimated number of patients per arm was 448 (total
in the study = 1,792). Although the unit of allocation was
the PHCPs, these are formed of several healthcare cen-
ters throughout the territory that only share administra-
tive management and some services. Also, this effect
was already controlled by means of the stratification.
Therefore, we considered that the intra-class correlation
within PHCP was insignificant, and we used instead the
intra-class correlation for FCU, that is, among patients
served by the same FCU. Although small, we consider
that this correlation is significant.
However, sample size was increased by an additional
30% to accommodate for expected losses to follow-up
and to warrant the presence of each arm in the study in
the different islands. Hence, we aimed for a total sample
size of 2,330.
Cost-effectiveness analysis
We will undertake a detailed analysis of the cost and the
cost-effectiveness of each of the four groups in compari-
son to the others. Our analysis will conform to accepted
economic evaluation methods. We will estimate cost and
cost-effectiveness for the ‘within-trial’ period (2 years/
short-run model) and also over the expected lifetime of
the patient (lifetime/long-run model).
Short-run model The cost-effectiveness measures in
the two-year model will be the incremental cost per
quality-adjusted life year (QALY) gained. QALYs will be
calculated based on the HRQoL data collected during
the trial. HRQoL will be measured according to the EQ-
5D-5 L, which will be collected at baseline and at each
follow-up visit for each individual patient. Patient-
specific utility profiles will be constructed assuming a
straight line relation between each of the patients’ EQ-
5D-5 L scores at each follow-up point. The QALYs expe-
rienced by each patient from baseline to 2 years will be
calculated as the area underneath this profile. We will
investigate differences in baseline characteristics and, if
necessary, use regression methods to control for them.
As explained above, costs included in the analysis are those
incurred by the healthcare service. Cost-effectiveness
will be calculated as the incremental cost-effectiveness
ratio (ICER) by dividing the estimated differences in
costs by the differences in effects observed. Nonpara-
metric methods to calculate confidence intervals around
the ICER based on bootstrapped estimates of the mean
cost and effect differences will be used. The bootstrap
replications will also be used to construct a cost-
effectiveness acceptability curve, which will reveal theprobability that each alternative is cost-effective at
2 years for different values of willingness to pay for an
additional unit of effectiveness. We will also subject the
results to extensive deterministic (one-, two-, and multi-
way) sensitivity analysis.Long-run model The interventions under evaluation in
this study are likely to have an impact beyond the trial
period. To capture these potential effects, we will ex-
trapolate the results to an extended time horizon in the
analysis, i.e., considering the remaining life expectancy
of the patients.
We will consider the potential application of the Centers
for Disease Control-Research Triangle Institute (CDC-
RTI) Diabetes Cost-Effectiveness Model [50] to estimate
long-term outcomes in our population. The CDC-RTI
Diabetes Cost-Effectiveness Model is a validated simula-
tion model of disease progression and cost-effectiveness
for T2DM based on data from the UK Prospective Dia-
betes Study (UKPDS) [51] and other sources. The aim of
this model is to simulate the development of T2DM-
related complications on three microvascular disease
paths (nephropathy, neuropathy, and retinopathy) and
two macrovascular disease paths (coronary heart disease
and stroke). The model structure is based on a Markov
model which simulates the progression of a patient based
on estimated transition probabilities between possible dis-
ease states. In the CDC-RTI Diabetes Cost-Effectiveness
Model, transition probabilities depend on risk factors—
including HbA1c and cholesterol concentrations.
Following decisions about model structure to estimate
future outcomes, a list of parameter estimates required
for the model will be developed. Data from the trial will
be used to input the model in order to estimate the
long-term cost-effectiveness of the different alternatives,
alongside relevant data from the published literature.
The specific details of the data to be used to populate
the model will be determined following the development
of the structure and the systematic literature searches to
identify available evidence. The cost-effectiveness meas-
ure will again be expressed in terms of the ICER for each
alternative after discarding dominated strategies. We will
undertake deterministic (one-, two-, and multiway) and
probabilistic sensitivity analysis, the latter assuming ap-
propriate distributions and parameter values [52].Duration of fieldwork
Fieldwork is estimated to last 3 years. The first year to
complete recruitment of patients and healthcare pro-
viders in primary care and the following 2 years for
follow-up and measurement. As interventions are main-
tained over time, the period of intervention and follow-
up overlap (Figure 1).
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Trial monitoring is the responsibility of a research team
in charge of all quality control activities, assessing adher-
ence to the trial protocol: timely work plan execution and
comprehensiveness of data acquisition and data quality
(databases have been designed to avoid downloading in-
appropriate values for every variable). The interactive
group sessions for patients and family members, as well as
those for primary care physicians and nurses, are being re-
corded to monitor the quality of the intervention and its
adherence to the predefined script.
Trial status
Recruitment is complete and the trial is ongoing.
Discussion
The ongoing INDICA study is a four-arm RCT involving
all main actors playing a role in decision-making in
T2DM (patients, families, physician and nurses). The
INDICA study will assess the comparative effectiveness
and cost-effectiveness of usual care for T2DM patients
against three multicomponent education and coaching
interventions. These interventions combine conventional
group educational and training activities with different
ICT-based interventions to guide the decisions of T2DM
patients, families, and primary care healthcare profes-
sionals, according to evidence-based guidelines. The pri-
mary analysis is aimed at comparing the mean 24-month
HbA1c (operationalized as HbA1c % change from base-
line) among patients with T2DM whose PHCPs were
assigned to the usual care group with the mean 24-
month HbA1c % change among patients with T2DM
whose PHCPs were assigned to the three different inter-
vention groups. The study used cluster randomization to
reduce the risk of contamination bias, since the educa-
tional parts of the multicomponent interventions for pa-
tients and healthcare professionals were applied to
groups.
The importance of glucose control in T2DM has been
confirmed in a meta-analysis [53]. The high incidence of
macrovascular complications, such as myocardial infarc-
tion, stroke, and lower-limb amputations, are a major
cause of disability, mortality, and economic losses. Micro-
vascular complications, including retinopathy, neuropathy,
and kidney disease also account for a highly significant
morbidity, mortality, and economic burden [54] among
patients with T2DM. The incidence of these complications
and their healthcare and social and economic conse-
quences is higher in the Canary Islands than in the rest of
Spain and most western countries [2-4].
The interventions assessed by the INDICA study are
based on the conceptual framework of behavioral change
and patient-centered care [29,34]. There is increasing
evidence that good self-care is related to improvedT2DM outcomes [10,11,55,56]. Provider education and
continuous feedback to patients and the use of reminders
have been associated with improvements in provider ad-
herence to guidelines and with clinically significant im-
provements in patient outcomes [10,11,55,56]. Although
ICT-based studies to improve diabetes self-management
have grown rapidly, there is a substantial discrepancy be-
tween the demand for this healthcare delivery mode and
the scientific evidence supporting its efficacy and cost-
effectiveness. Most published studies are focused on single
interventions exclusively aimed at patients and are limited
by methodologic deficiencies related to small-sample sizes
and inconsistent selection of outcomes and measurement
instruments, as well as short follow-up periods [57]. Al-
though several studies assessing the effectiveness of ICT-
based interventions on diabetes outcomes have reported
small but significant effect-sizes [18-22,58], very few have
assessed cost-effectiveness. Cost-effectiveness is especially
relevant for the assessment of ICT-based interventions
aimed at prevalent chronic diseases, given that the highest
costs of the interventions correspond to the development
of ICT applications whose effectiveness will become
blurred over time as well as with their use by thousands of
patients and physicians. In the current times of financial
crisis, interventions not only have to prove effectiveness
but also cost-effectiveness to reduce uncertainty in health-
care policy decision-making to contribute to the economic
sustainability of public healthcare services. Consequently,
while much is promised by electronic communications
and tele-health interventions, there is a lack of robust in-
formation to support decisions at patient, clinician, and
healthcare policy decision-maker level.
The current worldwide availability of mobile phones
and internet use across socio-economic, gender, and age
groups, combined with their unique ability to process
and communicate data in real-time, make them an ideal
platform to create simple, effective, and real-time dia-
betes management programs that can be used for large
groups of patients. Few previous studies of electronic
communication interventions for T2DM are random-
ized, include a control group, or involve more than one
treatment group to evaluate complex or multicompo-
nent interventions for all actors involved, not only from
the effectiveness perspective but also the assessment of
cost-effectiveness. This approach will improve transfer-
ability by extending the usefulness of the expected re-
sults beyond patients and clinicians in primary care to
healthcare policy decision-makers.
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